A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Condition:   Relapsed or Refractory Acute Lymphoblastic Leukemia Intervention:   Biological: single dose of CNCT19 Sponsor:   Juventas Cell Therapy Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials